Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10485MR)

This product GTTS-WQ10485MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10485MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1184MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ13201MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ13473MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRS-343
GTTS-WQ8475MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2037MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ1528MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ13032MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ9047MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMC-18F1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW